To include your compound in the COVID-19 Resource Center, submit it here.

Heplisav: Phase III data

Top-line data from a double-blind, U.S. Phase III trial in 2,449 healthy volunteers ages 40-70 showed that Heplisav met the primary and secondary immunogenicity endpoints of non-inferiority and superiority, respectively, to Engerix-B in the proportion of subjects achieving a seroprotective immune response, defined

Read the full 434 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers